Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 1.00 |
| ▸ | CTSB | P07858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CTSG | P08311 | 1/20 | 1.00 |
| ▸ | CAPN9 | O14815 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aloxistatin SCHEMBL21981208 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981210 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL12620387 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL254426 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL483320 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL22273610 | 0.93 | CAPN1 (0.87) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL9314220 | 0.93 | CAPN1 (0.86) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653616 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653864 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL1804811 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114368-A1 | COMPOSITIONS AND METHODS RELATING TO PEDIATRIC NEUROMUSCULAR DISEASES AND NEUROGENERATIVE DISORDERS | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO | 2025-04-10 | — | — | US | claimed |
| US-12116597-B2 | Autophagy as a therapeutic target for intracranial aneurysm | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-15 | — | — | US | claimed |
| CN-118766947-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118662520-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2024-09-20 | — | — | CN | claimed |
| EP-3188746-B1 | TARGETING CAPN9 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES | UNIV JOHNS HOPKINS (US) | 2024-06-19 | — | — | EP | claimed |
| US-20230270715-A1 | AUTOPHAGY AS A THERAPEUTIC TARGET FOR INTRACRANIAL ANEURYSM | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-31 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| CN-110109348-B | Depth-based hydraulic proportional valve bidirectional dead zone compensation method | 河南工学院 | 2023-03-10 | — | — | CN | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4346772-B1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4132651-B1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3651860-B1 | AGENT FOR PREVENTING OR AMELIORATING UNEVEN SKIN TONE | KAO CORP (JP) | 2026-03-04 | — | — | EP | disclosed |
| WO-2022046706-A2 | ASSAY FOR SARS-COV-2 INFECTION OF VULNERABLE HUMAN CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220026415-A1 | A METHOD FOR SCREENING A THERAPEUTIC AGENT FOR CANCER USING BINDING INHIBITOR OF CYCLIN-DEPENDENT KINASE 1 (CDK1)-CYCLIN B1 AND RETINOIC ACID RECEPTOR RESPONDER 1 (RARRES1) GENE KNOCKOUT ANIMAL MODEL | NATIONAL CANCER CENTER (KR) | 2022-01-27 | — | — | US | disclosed |
| EP-3390439-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | Dyax Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3334343-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Dyax Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017106504-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | DYAX CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017027771-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | DYAX CORP. (US) | 2017-02-16 | — | — | WO | disclosed |